Keryx Biopharm Inc (KERX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | 09-2017 | |
| Sales | 28,036 | 25,749 | 21,751 | 18,682 | 14,996 |
| Cost of Goods | 8,373 | 8,415 | 10,278 | 8,279 | 6,694 |
| Gross Profit | 19,663 | 17,334 | 11,473 | 10,403 | 8,302 |
| Operating Expenses | 34,722 | 37,900 | 34,503 | 41,694 | 32,715 |
| Operating Income | -14,686 | -20,151 | -22,752 | -31,012 | -23,719 |
| Other Income | -2,309 | -1,367 | 222 | 288 | 241 |
| Pre-tax Income | -16,995 | -21,518 | -22,530 | -30,724 | -23,478 |
| Income Tax | N/A | N/A | -634 | -295 | 20 |
| Net Income Continuous | -16,995 | -21,518 | -21,896 | -30,429 | -23,498 |
| Net Income | $-16,995 | $-21,518 | $-21,896 | $-30,429 | $-23,498 |
| EPS Basic Total Ops | -0.14 | -0.18 | -0.18 | -0.25 | -0.20 |
| EPS Basic Continuous Ops | -0.14 | -0.18 | -0.18 | -0.25 | -0.20 |
| EPS Diluted Total Ops | -0.14 | -0.18 | -0.18 | -0.25 | -0.20 |
| EPS Diluted Continuous Ops | -0.14 | -0.18 | -0.18 | -0.25 | -0.20 |
| EPS Diluted Before Non-Recurring Items | N/A | N/A | -0.18 | -0.26 | -0.20 |
| EBITDA(a) | $-12,282 | $-18,672 | $-22,562 | $-30,824 | $-23,551 |